AstraZeneca/Acerta Pharma
Acalabrutinib Granted Breakthrough Therapy Designation for MCL
Acalabrutinib was granted breakthrough therapy designation for treatment of patients with mantle cell lymphoma ...
AUGUST 2, 2017
Load more